


Atty. Dkt. No. 355908-3303



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony E. BOLTON, et al


Title: PEPTIDE-CARRYING BODIES
FOR IMMUNE RESPONSE

Appl. No.: 10/502,149

Filing Date: 7/19/2004

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

<p align="center">CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.</p> <p align="center"><u>Rene Campos</u> (Printed Name)</p> <p align="center"> (Signature)</p> <p align="center"><u>11.22.04</u> (Date of Deposit)</p>
--

TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents in the above-identified application.

1. Second Information Disclosure Statement (3 pgs.);
2. PTO Form 1449 (1 pg.);
3. Six (6) references as cited (B1-B2 and C1-C4);
4. International Search Report – PCT/CA03/00066- (5 pgs); and
5. Return postcard.

[X] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise


improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date 11-22-04

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 251-1103
Facsimile: (650) 856-3710


By 
Gerald F. Swiss
Attorney for Applicant
Registration No. 30,113



Atty. Dkt. No. 355908-3303

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony E. BOLTON, et al
Title: PEPTIDE-CARRYING BODIES
FOR IMMUNE RESPONSE
Appl. No.: 10/502,149
Filing Date: 7/19/2004
Examiner: Not Yet Assigned
Art Unit: Not Yet Assigned

<p align="center">CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.</p> <p align="center"><u>Rene Campos</u> (Printed Name)</p> <p align="center"> (Signature)</p> <p align="center"><u>11-22-04</u> (Date of Deposit)</p>
--

SECOND INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to OG Notice dated August 5, 2003, *Information*

Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO-1449 was cited as being relevant during the prosecution of the corresponding International application. A copy of the International Search Report in PCT/CA03/00066 is attached setting forth the portion of each document considered relevant by the examiner. An English-language counterpart of the foreign-language documents has not been provided. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP§609).

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.


The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date 11-22-04

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 251-1103
Facsimile: (650) 856-3710

By Gerald F. Swiss
Gerald F. Swiss
Attorney for Applicant
Registration No. 30,113

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 355908-3303		SERIAL NO. 10/502,149	
 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Anthony E. BOLTON, et al			
				FILING DATE 7/19/2004		GROUP ART UNIT Not Yet Assigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,840,691	11/24/1998	Furcht et al.			
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	B1	EP0298820	1/11/1989	Europe [English Abstract]			
	B2	JP8183740	7/16/1996	Japan [English Abstract]			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	C1	Lestini et al. "Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery" <i>Journal of Controlled Release</i> 78:235-247 (2002)					
	C2	Sjaastad et al. "Feedback regulation of cell-substratum adhesion by integrin-mediated intracellular Ca ²⁺ signaling" <i>Proc. Natl. Acad. Sci. USA</i> 91:8214-8218 (1994)					
	C3	Adderley et al. "Glycoprotein IIb/IIIa Antagonists Induce Apoptosis in Rat Cardiomyocytes by Caspase-3 Activation" <i>J. of Biological Chemistry</i> 275(8):5760-5766 (2000)					
	C4	Ito et al. "Tcell adherence and mucosal injury in ulcerative colitis: Involvement of integrin-fibronectin interaction in situ" <i>J. Gaster.</i> 30:70-72 (1995)					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							